REGULATORY

• Govt’s FY2017 Budget Includes 32 Trillion Yen for Social Security Spending
  December 26, 2016

• PM Abe’s Panel to Keep Vigilant Eyes on Drug Prices, Reimbursement Fees
  December 22, 2016

• Chuikyo to Discuss Annual Price Revision Plan in Concert with CEFP: Official
  December 22, 2016

• Claims for Health Damage Compensation Continued to Increase in FY2015, Rising to 1,566: PMDA
  December 22, 2016

• Blanket Driving Ban for 3 SNRIs Eased: MHLW
  December 21, 2016

• MHLW Begins Drafting Manual on Proper Use of Antibiotics for Clinicians
  December 21, 2016

• Quarterly Price Reviews for Indication-Added Drugs Likely to Get Underway in FY2017, Annual Scheme in FY2018: Officials
  December 21, 2016

• Four Ministers Map Out Basic Policy for Drug Pricing Revamp
  December 21, 2016

• Basic Policy for Drastic Reform of Drug Pricing System
  December 20, 2016

• MHLW OKs Tecfidera, Otezla, Other Drugs
  December 20, 2016

• Natural Rise in Social Security Spending to Be Curbed to 500 Billion Yen
  December 20, 2016

• Govt Clarifies Its Goals in Healthcare R&D Plan, Aims to Begin Clinical Trials for iPS-Based Therapies by 2020
  December 19, 2016

• Chuikyo Kicks Off Debates on 2018 Dual Reform of Healthcare and Long-Term Care Insurance
  December 15, 2016

• HIV Med Descovy OK’ed for NHI Price Listing on Dec. 21
  December 15, 2016

• PD-L1 Expression Testing Won’t Be a Must for Opdivo, but Clarification Needed: Chuikyo
  December 15, 2016

• MHLW Drafts Optimal Use Guidelines for Opdivo in NSCLC
  December 14, 2016

• Diet members Aim to Create Non-Partisan Forum for Healthcare Industry
  December 14, 2016

• Survey Method, Product Scope for Annual Revisions to Be Discussed in 2017
  December 14, 2016

• LDP Health Panel Chair Submits Letter Opposing Annual Price Revisions
  December 13, 2016

• PMDA Reviewing Risk of Hep B Virus Reactivation for Revlimid
  December 13, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 257
• 258
• 259
• 260
• 261
• 262
• 263
• 264
• 265
• …
• Next ›
• 最終 »